Though Novavax’s COVID-19 vaccine candidate could appeal to those wary of mRNA-based vaccines, don’t expect it to spur that much change, health experts told CNBC July 15.
Read the full post on Becker's Hospital Review - Healthcare News
Novavax approval won’t boost vaccination rate, experts say
